FDA and EMA Submissions, Partnerships, Milestones, Participation Withdrawals, and Prequalifications - Research Report on Johnson & Johnson, Novartis, AstraZeneca, Astex Pharmaceuticals, and Sanofi

NEW YORK, September 10, 2013 /PRNewswire/ --

Today, Investors' Reports announced new research reports highlighting Johnson & Johnson (NYSE: JNJ), Novartis AG (NYSE: NVS), AstraZeneca PLC (NYSE: AZN), Astex Pharmaceuticals, Inc. (NASDAQ: ASTX), and Sanofi (NYSE: SNY). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Johnson & Johnson Research Report

On September 3, 2013, Johnson & Johnson announced that its pharmaceutical research arm, Janssen Research & Development, LLC (Janssen), has submitted a Biologic License Application (BLA) and a Marketing Authorization Application (MAA) for siltuximab to the US Food and Drug Administration (FDA) and European Medicines Agency (EMA), respectively. According to Johnson & Johnson, siltuximab is used in treating patients with multicentric Castleman disease (MCD) who are HIV-negative and human herpes virus-8 (HHV-8)-negative. Peter F. Lebowitz, M.D., Ph.D., Global Oncology Therapeutic Area Head, Janssen, commented, "We're proud of our work on siltuximab. As a rare disease with a small patient population, MCD is an area of significant unmet need." Lebowitz explained, "Siltuximab works by targeting interleukin-6 which appears to be the critical driver of this disease. By focusing on core biologic mechanisms, we now have the potential of helping patients with a condition that is challenging to treat." The Full Research Report on Johnson & Johnson - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.InvestorsReports.com/report/2013-09-08/JNJ]

--

Novartis AG Research Report

On September 6, 2013, Novartis AG (Novartis) announced its exclusive global licensing and research collaboration agreement with Regenerex LLC., for use of the Company's novel Facilitating Cell Therapy (FCRx) platform. The Company said that the FCRx will broaden the current Novartis cell therapy portfolio, which includes two novel cell therapy platforms initially being investigated in hematological malignancies. Dr. Timothy Wright, Global Head Development, Novartis Pharmaceuticals, stated, "As the field of biomedicine sits on the cusp of a new transformation, we are excited to announce this agreement which supports the Novartis leadership position in cell therapy." Wright continued, "Thirty years ago, Novartis developed ciclosporin, which changed transplantation treatment paradigms and enabled countless lives to be saved. Now, this collaboration, along with our internal cell therapy assets, has the potential to transform medicine once again through innovation." The Full Research Report on Novartis AG - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.InvestorsReports.com/report/2013-09-08/NVS]

--

AstraZeneca PLC Research Report

On September 4, 2013, AstraZeneca PLC (AstraZeneca) announced the enrollment of the first patient in the Phase III clinical programme for olaparib, an innovative oral poly ADP ribose polymerase (PARP) inhibitor being investigated for the treatment of BRCA mutated ovarian cancer. According to the Company, the Phase III SOLO (Study of OLaparib in Ovarian cancer) programme is designed to determine the benefit, by progression free survival, of olaparib as a maintenance monotherapy in BRCA mutated ovarian cancer patients who are in complete or partial response following platinum-based chemotherapy in the first line setting (SOLO 1), and in the relapsed setting (SOLO 2). Antoine Yver, Vice President and Head of Oncology in AstraZeneca's Global Medicines Development unit, stated, "This is a significant milestone for olaparib, and further evidence of AstraZeneca's commitment to invest in distinctive science in our core therapy areas, with a particular focus on high unmet need. We feel olaparib has real potential to significantly improve treatment decisions for this group of patients who currently have limited options, and to become the next important product in our growing oncology portfolio." The Full Research Report on AstraZeneca PLC - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.InvestorsReports.com/report/2013-09-08/AZN]

--

Astex Pharmaceuticals, Inc. Research Report

On September 6, 2013, Astex Pharmaceuticals, Inc. (Astex) announced that its management team members have withdrawn their participation from the three banking conferences at which the Company had previously planned to present. According to Astex, the three conferences were: the Rodman & Renshaw Annual Global Investment Conference, the Morgan Stanley Global Healthcare Conference, and the Stifel Healthcare Conference 2013. The Full Research Report on Astex Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.InvestorsReports.com/report/2013-09-08/ASTX]

--

Sanofi Research Report

On September 3, 2013, Sanofi announced that its vaccines division, Sanofi Pasteur has received a prequalification from the World Health Organization (WHO) for one of its quadrivalent vaccines, Menomune, which is used to prevent invasive meningococcal disease. According to the Company, the prequalification makes Menomune vaccine eligible for purchase by United Nations Agencies. Olivier Charmeil, President and CEO, Sanofi Pasteur, said, "Sanofi Pasteur's commitment to help protect against meningococcal disease began almost 40 years ago with the introduction of a monovalent vaccine that offered protection against serogroup A and a bivalent vaccine that offered protection against serogroups A and C." Charmeil added, "Our commitment to remaining at the forefront of advancing the prevention of meningococcal disease, worldwide, continues today." The Full Research Report on Sanofi - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.InvestorsReports.com/report/2013-09-08/SNY ]

----

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by an analyst. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
5. For any urgent concerns or inquiries, please contact us at [email protected].
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

Web address: InvestorsReports.com

SOURCE Investors' Reports